Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CYTO -MC $6 m--Covid data readout THIS week.. this low floater could explode on positive results
Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023
CYTO -MC $6 m--Covid data readout THIS week.. this low floater could explode on positive results
Strategic BentrioTM partnering or divestiture process enters decisive phase
Partnering or divestiture process for inner ear therapeutics assets ongoing
Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023
https://finance.yahoo.com/news/altamira-therapeutics-provides-end-2022-134700033.html
CYTO $5.40 -MC $6 m--Covid data readout THIS week.. this low floater could explode on positive results
Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023
Strategic BentrioTM partnering or divestiture process enters decisive phase
Partnering or divestiture process for inner ear therapeutics assets ongoing
https://finance.yahoo.com/news/altamira-therapeutics-provides-end-2022-134700033.html
CYTO $5.33 -MC $6 m--Covid data readout THIS week.. this low floater could explode on positive results
Strategic BentrioTM partnering or divestiture process enters decisive phase
Partnering or divestiture process for inner ear therapeutics assets ongoing
Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023
https://finance.yahoo.com/news/altamira-therapeutics-provides-end-2022-134700033.html
SNES $3 has only 670k shares out may benext HKD here
SNES $2.95 next HKD? only 670k O/S
CYTH now up 33% and still brutally underpriced at 18 million valuation
CYTH $1.60 -MC $16 m..Blockbuster in Phase 3 (NPC) and Phase 2 (Alzheimer)... one of the most underpriced low float biotech out there
https://cyclotherapeutics.com/pipeline/
CYTH up 23% next breakout opp
CYTH $1.50 -MC $15 m..Blockbuster in Phase 3 (NPC) and Phase 2 (Alzheimer)... one of the most underpriced low float biotech out there
CYTH $1.50 -MC $15 m..Blockbuster in Phase 3 (NPC) and Phase 2 (Alzheimer)... one of the most underpriced low float biotech out there
https://cyclotherapeutics.com/pipeline/
ORTX up 35%
SNES $2.90 -MC $2 m- O/S 670k shares next KALA ??
SNES $2.90 -MC $2 m- O/S 670k shares next KALA ??
(FBIO) $0.65 -MC $69 m -Cash $208 m...has 7x PHASE 3 Assets + 1x BLA submittedt today for a cancer drug
latest Preesentation
https://d1io3yog0oux5.cloudfront.net/_0e3a1eedf502058509a43e39d94cac3d/fortressbiotech/db/640/5958/pdf/FBIO+Corporate+Presentation+-+Dec+2022_website.pdf
(FBIO) $0.65 -MC $69 m -Cash $208 m...has 7x PHASE 3 Assets + 1x BLA submitted today for a cancer drug
latest Preesentation
https://d1io3yog0oux5.cloudfront.net/_0e3a1eedf502058509a43e39d94cac3d/fortressbiotech/db/640/5958/pdf/FBIO+Corporate+Presentation+-+Dec+2022_website.pdf
ORTX $0.48 Breakout imminent ..market cap $63m trading significantly below cash of $147 million . Company has already an approved drug in Europe and about to file BLA for FDA approval in Q1 .
ORTX $0.37 -MC $46 m-Cash $147 m --BLA filing imminent , they could get $100 million for their priority review voucher once drug is approved which expected later this year ...
Key Upcoming Clinical and Research Milestones ;
OTL-200 for MLD (U.S.): Conduct a pre-Biologics License Application (BLA) meeting with U.S. Food and Drug Administration (FDA) in the second half of 2022 in advance of a BLA submission timeline of late 2022 to early 2023.
OTL-203 for MPS-IH: Initiate a global registrational study in 2023.
DERM $1.40 low floater with 11 marketed drugs + one in Phase 3 trials and trading under cash ...Market Cap $24 million / Cash $35 million / Shares Out 17.6 million half of that owned by insiders ...
DERM $1.40 low floater with 11 marketed drugs + one in Phase 3 trials and trading under cash ...Market Cap $24 million / Cash $35 million / Shares Out 17.6 million half of that owned by insiders ...
DERM $1.65 up 16% and still trading under cash and with 11 Drugs on market
DERM $1.40 may next KALA ...low floater with 11 marketed drugs + one in Phase 3 trials and trading under cash ...Market Cap $24 million / Cash $35 million / Shares Out 17.6 million half of that owned by insiders
(DERM) $1.20--MC $20m--11 x Marketed Drugs + another Drug in ongoing Phase 3 trial with data readout coming in Q2 ...Company trading at Cash balance of $35 million and annual revenue tops $70 million
Presentation
https://d1io3yog0oux5.cloudfront.net/_6e68aacef583dd1fa04a3b15d3eca146/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
CDTX 0.50 -FDA Decision in March ,, Stock trading under cash and has big Deals with Janssen ,Melinta & Mundipharma worth $1.8 BILLION for more information check out their presentation below
Market Cap $37 million
Cash $53 million
https://www.cidara.com/pipeline/
Presentation
https://www.cidara.com/wp-content/uploads/2022/11/Cidara-Corporate-Deck-November-11-16.pdf
MDWD up 13% after R/S -FDA Decision in 12 days
CDTX 0.51 -MC $36 m- Cash $51 m-- FDA Decision in March ,, has Deals with Janssen ,Melinta & Mundipharma worth $1.8 BILLION for more information check out their presentation below
https://www.cidara.com/pipeline/
Presentation
https://www.cidara.com/wp-content/uploads/2022/11/Cidara-Corporate-Deck-November-11-16.pdf
MDWD $1.60 -Good news + FDA decision in 13 days
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
https://finance.yahoo.com/news/mediwound-announces-positive-results-u-120000541.html
MDWD up 17% FDA approval in 16 days so there is still time for a nice runup
MDWD $1.29 FDA decision in 15 days ..likely to run like ACER which more than doubles ahead of the FDA decision
MDWD ---PDUFA date of January 1, 2023
LCI $0.61 -BIG Phase 3 data next week ..this one could double or triple on positive results
Completed Dosing of Subjects in the Pivotal Biosimilar Insulin Glargine Clinical Trial, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023
LCI $0.61 -BIG Phase 3 data next week ..this one could double or triple on positive news
Completed Dosing of Subjects in the Pivotal Biosimilar Insulin Glargine Clinical Trial, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023
MDWD $1.22 --FDA Decision in 16 days ..Cheap and well financed biotech with huge upside
Market Cap $51 million / Cash Balance $34.5 million additional 7.5 million milestone payment expected upon FDA approval
NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues
Company focused on the billion-dollar market opportunity with EscharEx Phase 3 clinical study to begin in first-half 2023
$30.5 million in gross proceeds raised; operating cash runway through 2025
MDWD $1.26 PDUFA date in 16 days ...the odd for approval is high
NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues
LABP $0.34 volume going up looks like breakout is imminent
LABP $0.32 potential buyout target here
Market Cap $12 m--Cash balance $48 m .
Major Shareholders
https://www.cnbc.com/quotes/labp?tab=ownership
Pipeline
https://landosbiopharma.com/product-candidates/our-pipeline/
LABP $0.32 potential buyout target here
Market Cap $12 m--Cash $48 m .
Major Shareholders
https://www.cnbc.com/quotes/labp?tab=ownership
Pipeline
https://landosbiopharma.com/product-candidates/our-pipeline/
LABP $0.30--MC $12m--Cash $48 m ..dirt cheap biotech with nice pipeline , a potential buyout target
Pipeline
https://landosbiopharma.com/product-candidates/our-pipeline/
LABP $0.30--MC $12m--Cash $48 m ..dirt cheap biotech with nice pipeline , a potential buyout target
Pipeline
https://landosbiopharma.com/product-candidates/our-pipeline/
MDWD $1.28 --FDA Decision in 2 Weeks ..Cheap and well financed biotech with huge upside
Market Cap $52 million / Cash Balance $34.5 million additional 7.5 million milestone payment expected upon FDA approval
NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues
Company focused on the billion-dollar market opportunity with EscharEx Phase 3 clinical study to begin in first-half 2023
$30.5 million in gross proceeds raised; operating cash runway through 2025
Presentation
https://ir.mediwound.com/static-files/0ea1057e-b20d-4acf-914a-e5e344982438